Roche presenta "resultados robustos" de Vabysmo en la degeneración macular
Roche presenta "resultados robustos" de Vabysmo en la degeneración macular
Roche has presented robust evidence on the long-term efficacy of Vabysmo in the treatment of neovascular age-related macular degeneration. The data confirm that the drug maintains visual stability and anatomical improvements after four years of use, enabling a large majority of patients to reduce the frequency of injections. This highlights its durability and safety, offering a more convenient solution for chronic conditions that threaten vision. Furthermore, a study specifically conducted in Asia demonstrates promising results for polypoidal choroidal vasculopathy, a severe subtype of the disease. Vabysmo achieved significant improvements in visual acuity and resolution of abnormal vascular lesions in the retina. The drug’s good tolerability in this context reinforces its profile as a versatile therapeutic option capable of halting vision loss in diverse populations with complex clinical needs. This information is relevant to the open data movement because it exemplifies how transparency in clinical results, particularly when shared at scientific congresses, facilitates independent verification and the replicability of medical findings. By validating the real-world efficacy of new therapies, these open data support evidence-based decision-making, which is essential for optimizing resources in healthcare systems and ensuring that approved treatments meet the effectiveness and public safety standards required by the global scientific community.
Source: bolsamania.comPublished on 2025-09-09